Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | AHR | P35869 | 1/20 | 0.56 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 6/20 | 0.51 |
| ▸ | HTR1A | P08908 | 4/20 | 0.51 |
| ▸ | HTR6 | P50406 | 4/20 | 0.51 |
| ▸ | HTR2C | P28335 | 3/20 | 0.50 |
| ▸ | HTR1D | P28221 | 2/20 | 0.50 |
| ▸ | HTR1B | P28222 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19134737 | 0.88 | MEN1 (0.55) | MEN1KMT2ACYP3A4MAPTAHR | |
| SCHEMBL22601514 | 0.87 | HTR6 (0.46) | MEN1KMT2ACYP3A4MAPTAHR | |
| SCHEMBL12991968 | 0.85 | MEN1 (0.51) | MEN1KMT2ACYP3A4MAPTAHR | |
| SCHEMBL73842 | 0.84 | MEN1 (0.62) | MEN1KMT2ACYP3A4MAPTAHR | |
| SCHEMBL16366298 | 0.83 | MEN1 (0.53) | MEN1KMT2ACYP3A4MAPTAHR | |
| SCHEMBL20665499 | 0.83 | HTR2A (0.56) | MEN1KMT2ACYP3A4MAPTAHR | |
| SCHEMBL11821215 | 0.83 | MEN1 (0.53) | MEN1KMT2ACYP3A4MAPTAHR | |
| SCHEMBL11816093 | 0.81 | MEN1 (0.55) | MEN1KMT2ACYP3A4MAPTAHR | |
| SCHEMBL11817984 | 0.81 | MEN1 (0.54) | MEN1KMT2ACYP3A4MAPTAHR | |
| SCHEMBL19135068 | 0.81 | MEN1 (0.50) | MEN1KMT2ACYP3A4MAPTAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11638762-B2 | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors | SEAGEN INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-11229708-B2 | Conjugates of quaternized tubulysin compounds | SEAGEN INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20190314519-A1 | TARGETED DELIVERY OF NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEATTLE GENETICS, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190015517-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEATTLE GENETICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20170275334-A1 | LINEAR PEPTIDE ANTIBIOTICS | RQX PHARMACEUTICALS, INC. | 2017-09-28 | — | — | US | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170247412-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | SEATTLE GENETICS, INC. (US) | 2017-08-31 | — | — | US | disclosed |
| US-9708368-B2 | Linear peptide antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-RE42624-E1 | Methods of using macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. (CA) | 2011-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247412-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | CD47, CD44, MSR1 | MEN1 600/4885KMT2A 1557/4885CYP3A4 4515/4885 |
| US-20170275334-A1 | LINEAR PEPTIDE ANTIBIOTICS | SPAST, PEPD, NPEPPS | MEN1 3672/4885KMT2A 2316/4885CYP3A4 4722/4885 |
| US-20190314519-A1 | TARGETED DELIVERY OF NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | NAMPT, NME4, NNMT | MEN1 1915/4885KMT2A 3195/4885CYP3A4 4869/4885 |
| US-11229708-B2 | Conjugates of quaternized tubulysin compounds | LCK, UACA, TEKT1 | MEN1 126/4885KMT2A 2306/4885CYP3A4 4730/4885 |
| US-20190015517-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | LCK, UACA, TEKT1 | MEN1 126/4885KMT2A 2306/4885CYP3A4 4730/4885 |
| US-11638762-B2 | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors | NAMPT, NME4, NNMT | MEN1 1915/4885KMT2A 3195/4885CYP3A4 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.